what incentives do we need to introduce into the market, andmarket, and we can talk about the role ofincentive and purchasing strategies. he mentioned an important one, does the drug worked the way it looked like it did in trial? what is the hurdles, the roadblocks but we need to get over in order to make these arrangements work. let's talk about that for a bit and come back to thinking of new purchasing strategies, the move toward value -based payment comeau what would be incentives and what would be obstacles that we need to get over? >> we started working on this in the last. probably four years ago. come work with the barriers as we have gotten a few contracts up and running. one of the barriers is the fact that when you run a clinical trial and get approval what is in your label is the basis of the outcome contract. for example, if we studied the reduction in mortality and first-time hospitalization those of the endpoints we are allowed to contract on. if they want to look at total hospitalization, x, y, or z there is no flexibility for us to be able to actually put that in the c